Score Your Stock

US stock · figures in US dollars · scored on full-year results

West Pharmaceutical Services West Pharmaceutical Services, Inc. Common Stock

WST · Healthcare · Medical Instruments & Supplies
Top 28% of scored stocks
OkayTop 28% of scored stocks
Weak Spot

West Pharmaceutical Services scores 63/100 on fundamentals: in the top 28% of 503 scored S&P 500 stocks. Its strongest area is Financial Safety (100/100); its weakest is Price Fairness (0/100). It carries 1 warning flag: Weak Spot.

Best
Financial 100
Weakest
Price 0
  • Carries a Weak Spot flag

A financially strong, expensively priced stock, but price fairness needs attention.

What looks good
What to watch
Mkt capUS$ 28.8b#332 of 503 in the S&P 500EPSUS$ 7.81P/E45.1×✗ vs sector median 29.6×P/B9.7×✗ vs sector median 3.7×Div yield0%Bottom 22% in the S&P 50052w range · 88% of range223.83438.27
as of 31 Oct 2026

Nearby peers

Ranks #17 of 60 in Healthcare by score

#1Universal Health Services79#15Lilly (Eli)63#16Stryker63
#17West Pharmaceutical Services63
#18Medtronic62#19Cardinal Health61

One-Minute Summary

Why West Pharmaceutical Services scores 63

A financially strong, expensively priced stock, but price fairness needs attention.

What looks good
What to watch

Business Strength

80
Why 80?
Pillar score: (2 + 1 + 1 + 2 + 2) = 8 of 10 points → 80
Return on Equity (ROE)22%Strong4-Year Revenue Growth+5%/yrOkay4-Year Profit Growth+2%/yrOkayNet Profit Margin19%StrongQuarterly Momentum+12%Strong
Show 3 charts

Net Profit & Equity, with ROE

Net Profit ↑ +7.7%Equity ↑ +3%ROE % 21.5%
Net ProfitEquityROE %
593m493m494m639m2.9b2.7b3.2b3.0b202320242025TTM20.6%18.4%15.5%21.5%

Revenue & Net Profit, with Net Margin

Revenue ↑ +15.2%Net Profit ↑ +7.7%Net Margin % 18.8%
RevenueNet ProfitNet Margin %
2.9b2.9b3.1b3.4b593m493m494m639m202320242025TTM20.1%17%16.1%18.8%

Sales grew about 15.2% over 4 years: customers keep spending more with this company.

Profit has moved sideways: stable, but not compounding your money faster each year.

Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)

Revenue ↑ +16.8%Net Profit ↑ +13.2%Net Margin % 17.7%
RevenueNet ProfitNet Margin %
747m749m698m767m805m805m845m872m136m130m90m132m140m132m139m154mQ3'24Q4'24Q1'25Q2'25Q3'25Q4'25Q1'26Q2'2618.2%17.4%12.9%17.2%17.4%16.4%16.4%17.7%
▼▼▼▲▬▬▲▲

Sales grew about 16.8% over the last 8 quarters: customers keep spending more with this company.

Profit grew about 13.2% over the last 8 quarters: the business is keeping more of what it earns.

Why 100?
Pillar score: (2 + 2 + 2) = 6 of 6 points → 100
Debt-to-Equity0.1×StrongCurrent Ratio2.8×StrongInterest Coverage98.5×Strong
Show 2 charts

Debt vs Equity, with D/E ratio

Total Debt → -1.3%Equity ↑ +3%D/E 0.1×
Total DebtEquityD/E
309m302m321m305m2.9b2.7b3.2b3.0b202320242025TTM0.1×0.1×0.1×0.1×

Borrowings have stayed roughly level: manageable, as long as profits stay healthy.

Short-term assets vs bills, with Current Ratio

Current Assets ↓ -6.2%Current Liabilities ↓ -4.1%Current Ratio 2.8×
Current AssetsCurrent LiabilitiesCurrent Ratio
1.9b1.5b2.0b1.8b672m550m655m644m202320242025TTM2.9×2.8×3×2.8×
Why 50?
Pillar score: (0 + 1 + 2 + 1) = 4 of 8 points → 50
Dividend Quality0%Weak
Payout ratio: 10%
Operating Cash FlowPositive but bumpyOkayFree Cash FlowPositive & growingStrongCash & Cash EquivalentsPartly healthyOkay
Show 3 charts

Operating vs Free Cash Flow

Operating CF ↓ -15.7%Free CF ↑ +9.4%
Operating CFFree CF
777m653m755m655m415m276m469m453m202320242025TTM

Cash keeps coming in, though unevenly: fine, but worth keeping an eye on.

Cash vs Total Debt

Cash ↓ -45.6%Total Debt → -1.3%
CashTotal Debt
854m485m791m464m309m302m321m305m202320242025TTM

Dividends per Share, with Yield

DPS (cents) ↑ +16.4%Yield % 0.2%
DPS (cents)Yield %
181819202020202121227377818520222023202420250.2%0.2%0.2%0.2%

Dividends per share have been maintained or raised: management shares the rewards with you.

Why 0?
Pillar score: (0 + 0 + 0) = 0 of 6 points → 0
P/E Ratio45.1×WeakP/B Ratio9.7×WeakPEG Ratio18.1Weak
Show chart

Share Price: Weekly Closes (not part of the score)

US$ 412.62US$ 321.71US$ 230.79Oct '25Feb '26Jun '26Oct '26

The share price is up about 46.7% over the past year.

Why 83?
Pillar score: (2 + 1 + 2 + 2 + 1 + 2) = 10 of 12 points → 83
Earnings ConsistencySteadyStrongDebt Trend (4yr)StableOkayShare Count Trend (4yr)-2%/yrStrongInventory vs Sales (4yr)-2.6 pp/yr vs salesStrongAsset Turnover Trend (4yr)+8.6%OkayQuarterly Consistency0 of 4 quarters downStrong
Show chart

Revenue vs Inventory, with Inventory % of Revenue

Revenue ↑ +15.2%Inventory ↑ +6.9%Inv. % of Rev. 13.7%
RevenueInventoryInv. % of Rev.
2.9b2.9b3.1b3.4b435m377m444m465m202320242025TTM14.7%13%14.4%13.7%
Ranks #17 of 60 in Healthcare by score

Sector peers

#1Universal Health Services79#15Lilly (Eli)63#16Stryker63
#17West Pharmaceutical Services (you)63
#18Medtronic62#19Cardinal Health61

Full Financial History

Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.

Financial YearRevenueNet ProfitOperating Cash FlowFree Cash FlowCapExCashTotal DebtShort-Term DebtEquityCurrent AssetsCurrent LiabilitiesTotal AssetsTotal LiabilitiesInventoryDividendsReturn on Equity (ROE)Net Profit MarginDebt-to-EquityCurrent RatioInterest CoverageDividend Payout RatioDiv yieldP/E RatioP/B RatioPEG Ratio
2026US$ 3.4bUS$ 638.9mUS$ 654.5mUS$ 453.4mUS$ -201.1mUS$ 464.1mUS$ 305.0mUS$ 19.5mUS$ 3.0bUS$ 1.8bUS$ 644.3mUS$ 4.1bUS$ 1.1bUS$ 464.7m-22%19%0.1×2.8×98.5×10%----
2025US$ 3.1bUS$ 493.7mUS$ 754.8mUS$ 468.9mUS$ -285.9mUS$ 791.3mUS$ 321.1m-US$ 3.2bUS$ 2.0bUS$ 654.9mUS$ 4.3bUS$ 1.1bUS$ 443.9mUS$ 85.0m16%16%0.1×3.0×1202.8×12%0%40.2×6.3×-
2024US$ 2.9bUS$ 492.7mUS$ 653.4mUS$ 276.4mUS$ -377.0mUS$ 484.6mUS$ 302.3m-US$ 2.7bUS$ 1.5bUS$ 550.4mUS$ 3.6bUS$ 961.1mUS$ 377.0mUS$ 81.0m18%17%0.1×2.8×196.2×12%0%49.0×9.0×-
2023US$ 2.9bUS$ 593.4mUS$ 776.5mUS$ 414.5mUS$ -362.0mUS$ 853.9mUS$ 309.0mUS$ 134.0mUS$ 2.9bUS$ 1.9bUS$ 671.8mUS$ 3.8bUS$ 948.5mUS$ 434.7mUS$ 77.0m21%20%0.1×2.9×78.6×10%0%43.3×8.9×2.2